AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) — Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced that the Company will report second quarter 2026 financial results on Tuesday, August 11, 2026. Mobia Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Conference Call and Webcast Details
Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of the call. A live and archived webcast can also be accessed via the News & Events page of the investor section of Mobia Medical’s website.
About Mobia Medical, Inc.
Mobia Medical, Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim® Paired VNS™ System is the first and only clinically validated, FDA-approved implantable solution designed to improve upper limb function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments. Therapy with the Vivistim® Paired VNS™ System combines targeted vagus nerve stimulation with functional movement to promote neuroplasticity and drive meaningful improvements in motor function. Mobia Medical is mobilizing patients, providers, and care partners to establish a better way forward in stroke care.
Investor Relations Contact
Louisa Smith
Gilmartin Group, LLC
investors@mobia.com
The article outlines how gentle chiropractic techniques support spinal alignment and movement in children and…
Collaboration creates a path to combine Signant's market-leading eCOA and digital endpoint capabilities with Lothar…
Amwell® is transforming virtual care delivery through its unified Amwell Platform, combining interoperability, clinical integration,…
US-based research peptide supplier broadens third-party analytical testing and per-batch Certificate of Analysis documentation across…
Montreal, Quebec--(Newsfile Corp. - September 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE:…
Accreditation affirms MMRO's commitment to responsible AI governance, human oversight, and clinical integrity.NOVI, Mich., Sept.…